Technetium-99m sulfur colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).

被引：0
|
作者：
Giovinazzo, Hugh
Kumar, Parag
Sheikh, Arif
Ivanovic, Marija
Walsh, Mark Doughty
Caron, Whitney Paige
Song, Gina
Whitlow, Ann B.
Newman, Suzanne E.
La-Beck, Ninh My
Kowalsky, Richard J.
Zamboni, Beth A.
Clarke-Pearson, Daniel L.
Brewster, Wendy R.
Van Le, Linda
Bae-Jump, Victoria Lin
Gehrig, Paola A.
Zamboni, William
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] UNC Eshelman Sch Pharm, Div Pharmacotherapy & Expt Therapeut, Chapel Hill, NC USA
[3] Mt Auburn Hosp, Cambridge, MA USA
[4] Texas Tech Univ, Abilene, TX USA
[5] Carlow Univ, Pittsburgh, PA USA
[6] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[7] UNC Eshelman Sch Pharm, Inst Pharmacogen & Individualized Therapy, Carolina Ctr Canc Nanotechnol Excellence, Div Pharmacotherapy & Expt Therapeut,Lineberger C, Chapel Hill, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5050
引用
收藏
页数：1
相关论文
共 11 条
  • [1] Technetium-99m Sulfur Colloid (TSC) as a phenotypic probe for predicting pharmacokinetics (PK) and palmar-plantar erythrodysesthesia (PPE) toxicity of PEGylated liposomal doxorubicin (PLD) in patients with recurrent epithelial ovarian cancer (EOC)
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Ivanovic, Marija
    Walsh, Mark D.
    Caron, Whitney P.
    Song, Gina
    Whitlow, Ann B.
    Newman, Suzanne E.
    La-Beck, Nihn
    Kowalsky, Richard J.
    Zamboni, Beth A.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Le, LindaVan
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William C.
    PHARMACOTHERAPY, 2012, 32 (10): : E310 - E310
  • [2] Technetium-99m sulfur colloid (TSC) as a phenotypic probe for the pharmacokinetics (PK) and pharmacodynamics (PD) of pegylated liposomal doxorubicin (PLD) in patients (pts) with recurrent epithelial ovarian cancer (EOC).
    Walsh, M. D.
    Giovinazzo, H.
    Sheikh, A.
    Ivanovic, M.
    Whitlow, A. B.
    Newman, S. E.
    La-Beck, N. M.
    Kowalsky, R. J.
    Zamboni, B. A.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] PALMAR-PLANTAR ERYTHRODYSESTHESIA (PPE) IN PATIENTS (PTS) WITH OVARIAN CANCER (OC) OR METASTATIC BREAST CANCER (MBC) TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD): AN OBSERVATIONAL STUDY
    Gonzalvez, M. L.
    Diaz, N.
    Redondo, A.
    Calvo, E. G.
    Illarramendi, J.
    Munarriz, B.
    Del Campo, J. M.
    Diez, J. Castellanos
    Santaballa, A.
    Lopez-Vivanco, G.
    ANNALS OF ONCOLOGY, 2010, 21 : 389 - 389
  • [4] Epidemiologic study to evaluate the treatment of palmar-plantar erythrodysesthesia (PPE) in patients (pts) with ovarian cancer (OC) or metastatic breast cancer (MBC) treated with pegylated liposomal doxorubicin (PLD).
    Gonzalvez, M. L.
    Diaz, N.
    Redondo, A.
    Calvo, E. G.
    Illarramendi, J. J.
    Munarriz, B.
    Del Campo, J.
    Castellanos Diez, J.
    Santaballa, A.
    Lopez-Vivanco, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer
    Hugh Giovinazzo
    Parag Kumar
    Arif Sheikh
    Kristina M. Brooks
    Marija Ivanovic
    Mark Walsh
    Whitney P. Caron
    Richard J. Kowalsky
    Gina Song
    Ann Whitlow
    Daniel L. Clarke-Pearson
    Wendy R. Brewster
    Linda Van Le
    Beth A. Zamboni
    Victoria Bae-Jump
    Paola A. Gehrig
    William C. Zamboni
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 565 - 573
  • [6] Technetium Tc 99m sulfur colloid phenotypic probe for the pharmacokinetics and pharmacodynamics of PEGylated liposomal doxorubicin in women with ovarian cancer
    Giovinazzo, Hugh
    Kumar, Parag
    Sheikh, Arif
    Brooks, Kristina M.
    Ivanovic, Marija
    Walsh, Mark
    Caron, Whitney P.
    Kowalsky, Richard J.
    Song, Gina
    Whitlow, Ann
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Zamboni, Beth A.
    Bae-Jump, Victoria
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (03) : 565 - 573
  • [7] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pegylated liposomal doxorubicin (PLD) pharmacokinetics (PK) in patients with recurrent ovarian cancer.
    Caron, W. P.
    Lay, J. C.
    Fong, A. M.
    La-Beck, N. M.
    Newman, S. E.
    Clarke-Pearson, D. L.
    Brewster, W. R.
    Van Le, L.
    Bae-Jump, V. L.
    Gehrig, P. A.
    Zamboni, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC).
    Muggia, F.
    Safra, T.
    Borgato, L.
    Gandhi, A.
    Mancinc, G.
    Gabizon, A.
    Liebes, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Cellular function of the mononuclear phagocyte system (MPS) as a phenotypic probe for pharmacokinetics (PK) and pharmacodynamics (PD) of PEGylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer.
    Caron, Whitney Paige
    Lay, John C.
    Kumar, Parag
    Fong, Alan M.
    La-Beck, Ninh My
    Newman, Suzanne E.
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Linda Van Le
    Bae-Jump, Victoria Lin
    Gehrig, Paola A.
    Zamboni, William
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC)
    Song, G.
    Moore, S.
    Tarrant, T.
    Dobrovolskaia, M.
    Barrow, D.
    Kumar, P.
    Newman, S.
    Bae-Jump, V.
    Gehrig, P.
    Zamboni, W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 39 - 40
12